Abstract：Objective To explore the effect of Gemcitabine combined with Cisplatin in the treatment of anthracyclineresistant and taxane-resistant advanced breast cancer.Methods A total of 76 patients with advanced anthracycline-resistant and taxane-resistant breast cancer who were admitted to our hospital from March 2017 to June 2019 were selected as the subjects.They were divided into two groups according to the random number table method, with 38 cases in each group.In the control group, Vinorelbine combined with Cisplatin was used, and in the experimental group,Gemcitabine combined with Cisplatin was adopted.The treatment effect, quality of life, and adverse reactions were compared between the two groups.Results The disease control rate (DCR) and objective response rate (ORR) of the experimental group were 50.00% and 86.84%, which were higher than those of the control group accounting for 26.32%and 44.74%, respectively, and the differences were statistically significant (P＜0.05).The Karnofsky performance status(KPS) score was (85.56±12.86) points, which was higher than that of the control group ([75.78±12.48]points), and the difference was statistically significant (P＜0.05).There were no significant differences in the incidence of anemia, fever,hair loss, renal impairment or liver impairment (P＞0.05).Conclusion Gemcitabine combined with cisplatin is safe for patients with anthracycline-resistant and taxane-resistant advanced breast cancer.
黄骏骢. 吉西他滨联合顺铂治疗耐蒽环类及紫杉类晚期乳腺癌的效果[J]. 中国当代医药, 2020, 27(13): 58-60转70.
HUANG Jun-cong. Effect of Gemcitabine combined with Cisplatin in the treatment of anthracycline-resistant and taxane-resistant advanced breast cancer. 中国当代医药, 2020, 27(13): 58-60转70.
He K，Wang X，Guan X，et al.Vinorelbine plus gemcitabine or cisplatin as first-line treatment of HER2-negative advanced breast cancer[J].Anticancer Res，2017，37（10）：5647-5653.
京公网安备 11010502046607号